Sam Singer is the CFO of Colossal Bioscience with extensive experience as a finance executive and investor in the biotech industry. Before joining Colossal, Sam was the Chief Financial Officer of Totus Medicines, a small molecule oncology focused biotechnology company where he was primarily responsible for growing the finance group, investor outreach and strategic messaging, including financial planning. Prior to Totus, Sam was an investor in the biotech sector leading analysis and valuation with a focus on gene editing companies.